Can Aspirin Ward Off Melanoma?

Continuous use of aspirin for 5 years or more reduces the risk of cutaneous melanoma by almost half, according to results of a case-control study. Continuous use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also reduces risk, but only by 25%.

 

The analysis compared long-term users (>5 years) with never-users and those who used aspirin or another NSAID among 400 patients with melanoma. Researchers did not identify the specific dose of aspirin taken by patients, but did determine that 70% of patients indicated exposure to aspirin for ≥4 times per week.

 

The study also sought benefits of long-term statin use as a chemopreventive; however, no significant protective effect was found.

 

The complete study is available in the July 2011 issue of the Journal of Investigative Dermatology (http://www.nature.com/jid/journal/v131/n7/full/jid201158a.html).

Related Items
Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Patients with Advanced Cutaneous Squamous-Cell Carcinoma
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Updates, Skin Cancer
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 published on October 30, 2014 in Skin Cancer
Immunotherapies Take Center Stage in Melanoma
F. Stephen Hodi, Jr, MD, Lynn M. Schuchter, MD, Mario Sznol, MD, Kim A Margolin, MD
TOP - August 2013 VOL 6, NO 3 published on September 5, 2013 in Skin Cancer
Recent Advances in the Treatment of Metastatic Melanoma
Megan Hagerty, PharmD, BCOP
TOP - Special Issue May 2012, Vol 5, No 3 published on May 24, 2012 in Skin Cancer
Lenalidomide Maintenance Therapy Benefits Patients With Multiple Myeloma
TOP - Daily published on May 15, 2012 in Skin Cancer
Vismodegib: A New Treatment Option for Basal Cell Carcinoma
Rhonda Williams
TOP - April 2012, Vol 5, No 2 published on April 30, 2012 in Skin Cancer
Peptide Vaccine Doubles Clinical Response Rate in Advanced Melanoma
TOP - Daily published on June 3, 2011 in Skin Cancer
Ipilimumab (Yervoy) Is First Melanoma Drug Approved in a Decade
Christin Melton
TOP - March/April 2011, VOL 4, NO 2 published on April 28, 2011 in Skin Cancer
Last modified: April 15, 2021